Market capitalization | $23.47m |
Enterprise Value | $24.99m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 10.34 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-23.68m |
Cash position | $9.51m |
EPS (TTM) EPS | $-9.87 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
3 Analysts have issued a Polypid Ltd forecast:
3 Analysts have issued a Polypid Ltd forecast:
Dec '23 | |
Current assets | 6.07 6.07 |
Fixed assets | 9.31 9.31 |
Total Assets | 15 15 |
Dec '23 | |
Equity | -2.10 -2.10 |
Debt capital | 17 17 |
Total Capital | 15 15 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/maxillofacial defects, while protecting from infections. PolyPid Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.
Head office | Israel |
CEO | Dikla Akselbrad |
Employees | 62 |
Founded | 2008 |
Website | www.polypid.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.